Abstract: A method for veterinary administration of medication to an animal, particularly a horse, is disclosed. The method involves inserting a capsule containing the medication, which is a liquid formulation, into a device connected to a tubular chamber. An atomizer is activated to atomize the medication, producing atomized medication. Before administration, a force is applied to a mask placed over the animal's muzzle, connected to the chamber. The atomized medication is then delivered to the animal. The liquid formulation, in some instances, comprises cells, cellular byproducts, or cell-derived products such as stem cells or products from human mesenchymal stem cells. This formulation may lack preservatives and may encompass peptides, proteins, growth factors, cytokines, exosomes, and extracellular vesicles. The delivery mechanism may involve deflating an air bladder to convey the atomized medication.

Abstract: The invention pertains to a capsule system for use with a medical device designed to administer atomized medication to patients. The system features a chamber containing the medication and an atomizer at a lower end for efficient drug delivery. Notably, the system incorporates a fluid sensor and electrical contacts to ensure proper operation and medication delivery. The capsule's design includes a housing with an asymmetrical transverse cross-sectional shape for unique fitting, and a tapered wall to direct medication towards the atomizer. The capsule may also connect to an external container or include a stopper for refilling medication. A specific embodiment features two chambers with a rupturing element to facilitate medication transfer. Another embodiment includes a removable container, like a vial, within the first chamber. This novel system provides improvements in accuracy, versatility, and user-friendliness, overcoming limitations in prior art.

Abstract: A retaining sleeve for retaining magnets inserted therein so that the magnets may be overmolded with a polymer pursuant to the manufacture of a rotor for an electric motor. The retaining sleeve comprising a generally cylindrical portion having an inner peripheral surface concentric about a central axis and a plurality of retaining partitions extending inward from the inner peripheral surface of the generally cylindrical portion, wherein the retaining partitions are configured to at least substantially limit movement of the magnets toward the central axis upon the magnets being inserted in the retaining sleeve at their respective locations inward of the inner peripheral surface of the retaining sleeve and between retaining partitions.

Abstract: The present invention relates to compositions and methods for preventing and treating periodontitis and other conditions. In particular, the present invention relates to oral bacteria for use in treating and preventing diseases and conditions.

Abstract: A retaining sleeve for retaining magnets inserted therein so that the magnets may be overmolded with a polymer pursuant to the manufacture of a rotor for an electric motor. The retaining sleeve comprising a generally cylindrical portion having an inner peripheral surface concentric about a central axis and a plurality of retaining partitions extending inward from the inner peripheral surface of the generally cylindrical portion, wherein the retaining partitions are configured to at least substantially limit movement of the magnets toward the central axis upon the magnets being inserted in the retaining sleeve at their respective locations inward of the inner peripheral surface of the retaining sleeve and between retaining partitions.

Abstract: The present invention is directed to novel sulfamide derivatives, pharmaceutical compositions comprising said compounds and methods for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, said compounds, either alone or as co-therapy with one or more anticonvulsant and/or anti-epileptic agents.

Abstract: The present invention is directed to novel sulfamide derivatives, pharmaceutical compositions comprising said compounds and methods for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, said compounds, either alone or as co-therapy with one or more anticonvulsant and/or anti-epileptic agents.

Abstract: The present invention relates to a novel gene which is associated with audiogenic seizures in mice. The gene is known as the Monogenic Audiogenic Seizure-susceptible gene or mass1. The product of the mass1 gene is designated MASS1. Nucleic acid molecules that encode for MASS I have been identified and purified. The sequence of murine mass1 can be found at SEQ ID NO: 1, and the sequence of human mass1 can be found at SEQ ID NO: 3. Mammalian genes encoding a MASS1 protein are also provided. The invention also provides recombinant vectors comprising nucleic acid molecules that code for a MASS1 protein. These vectors can be plasmids. In certain embodiments, the vectors are prokaryotic or eukaryotic expression vectors. The nucleic acid coding for MASS1 can be linked to a heterologous promoter. The invention also relates to transgenic animals in which one or both alleles of the endogenous mass1 gene is mutated. The invention further relates to a hearing impairment associated with the Frings MASS1 mutation.